M.D., FASCO
Medical Oncologist
2009 - present, American Board of Internal Medicine, Medical Oncology
2006 - 2016, American Board of Internal Medicine
2003, M.D., David Geffen School of Medicine at UCLA, Los Angeles, CA
1998, Magna Cum Laude, B.Sc., California State University Los Angeles Early Entrance Program, College in lieu of high school (program initiated at age 13)
2006-2009, Fellowship in Hematology/Oncology, City of Hope/Harbor-UCLA Medical Center, Los Angeles, CA
2004-2006, Internal Medicine, UCLA Medical Center, Los Angeles, CA
2003-2004, Internal Medicine, UCLA Medical Center, Los Angeles, CA
2020-present, Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
2016-present, Disease Team Chair, Bladder & Kidney Cancer
2016-2020, Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
2009-present, Co-director, Kidney Cancer Program, City of Hope, Duarte, CA
2009-2016, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
Sumanta (Monty) Kumar Pal, MD, FASCO, is a leader in the fight against kidney, bladder, and prostate cancers. At City of Hope® Cancer Center Duarte, he serves as co-director of the Kidney Cancer Program and leads the kidney and bladder cancer disease team, guiding groundbreaking research and patient care.
A prodigy who began college at age 13 and entered medical school at the University of California, Los Angeles (UCLA) by 17, Dr. Pal trained in oncology at City of Hope, where he has served on the faculty since 2009. Today, he is a driving force behind some of the most promising advancements in genitourinary cancer treatment.
Dr. Pal has authored more than 500 peer-reviewed publications in leading journals like Cancer Discovery, The Lancet, and Nature Medicine. He holds patents for novel therapies in prostate cancer and oversees one of the largest clinical trial portfolios for kidney and bladder cancer on the West Coast.
Through innovative partnerships with researchers at the Beckman Research Institute and urologists at City of Hope, Dr. Pal has built an integrated research program aimed at transforming care for patients facing currently incurable diseases. He is also a pioneer in precision medicine, identifying new targets in rare cancers and leading trials from early-stage development to late-phase studies.
Dr. Pal’s work is supported by the National Institutes of Health, SWOG, NCCN, and other top institutions. He is a member of several prestigious editorial boards, reflecting the high regard of his peers and the scientific community. His mission: to bring hope and new treatment options to patients everywhere through science, compassion, and collaboration.